Barinthus Biotherapeutics's total assets for Q3 2025 were $109.20M, a decrease of -15.71% from the previous quarter. BRNS total liabilities were $24.64M for the fiscal quarter, a -9.01% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.